



CONCORD DRUGS LIMITED

(A PHARMACEUTICAL FORMULATIONS UNIT)

CORPORATE OFFICE : # 3-11-1/1, L.B. Nagar, Hyderabad - 500 074. A.P. India.

Tel : 091-40-24037763, 24036379

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th September 2012

Rs in Lakhs

Sl. No.	Particulars	Three months	Three months	Three months	Half Year	Half Year	Year Ended
		30.09.2012	30.06.2012	30.09.2011	30.09.2012	30.09.2011	31.03.2012
		(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
1	Income from Operations :						
	(a) Net Sales / Income from Operations (Net of Excise Duty)	701.25	690.21	681.25	1,391.46	1,350.49	2,766.85
	(b) Other Operating Income	-	-	0.90	-	2.40	3.30
	Total Income From operations (net)	701.25	690.21	682.15	1,391.46	1,352.89	2,770.15
2	Expenses :						
	a) Operating Expenses	13.99	13.22	11.21	27.21	21.47	48.14
	b) Purchases of stock in trade	582.26	579.21	560.25	1,161.47	1,116.48	2,255.97
	c) Changes in inventories of finished goods Work-in-progress and stock-in-goods	0.10	(0.50)	6.25	(0.40)	8.50	29.87
	d) Employee benefits expense	7.85	7.24	5.68	15.09	11.80	23.20
	e) Depreciation and amortisation expense	17.35	17.35	14.52	34.70	29.04	59.87
	f) Power And Fuel	11.26	10.25	5.46	21.51	10.69	22.77
	g) Freight and Forwarding Expenses	3.85	3.65	3.55	7.50	7.00	13.38
	h) Other Expenses	19.21	18.92	13.20	38.13	27.40	59.00
	Total Expenses (a+b+c+d+e+f+g+h)	655.87	649.34	620.12	1,305.21	1,232.38	2,512.20
	Profit/(Loss) from operations before other Income and Finance costs (1-2)	45.38	40.87	62.03	86.25	120.51	257.95
3	Other Income						
		45.38	40.87	62.03	86.25	120.51	257.95
4	Profit/(Loss) From ordinary activities before finance Cost (3+/-)4)						
		12.27	12.25	9.63	24.52	18.88	39.42
5	Finance cost						
		33.11	28.62	52.40	61.73	101.63	218.53
6	Profit/(Loss) from ordinary activities before Tax (5+/-)6)						
		-	-	10.00	-	20.00	43.72
7	Tax expenses						
	(a) Current Tax	10.00	10.00	4.00	20.00	8.00	15.34
	(b) Deferred Tax	10.00	10.00	14.00	20.00	28.00	59.06
	Total (a+b)	23.11	18.62	38.40	41.73	73.63	159.47
8	Net profit/(loss) for the period (7+/-)8)						
		23.11	18.62	38.40	41.73	73.63	159.47
9	Minority interest						
		23.11	18.62	38.40	41.73	73.63	159.47
10	Net Profit/(Loss) after Taxes and minority interest (9+/-)10)						
		724.38	724.38	724.38	724.38	724.38	724.38
11	Paid up Equity Share Capital (Face value of Rs.10/- per share)						
		-	-	-	-	-	399.69
12	Reserves excluding Revaluation Reserve as per balance sheet at year end						
		0.32	0.26	0.53	0.58	1.02	2.20
13	Earnings Per Share(of Rs.10/- each) (not annualised)						
	a) Basic	0.32	0.26	0.53	0.58	1.02	2.20
	b) diluted						



Part II

Select Information for the Quarter and year Ended 30/09/2012

Sl. No.	Particulars	Three months	Three months	Three months	Half Year Ended	Half Year Ended	Year Ended
		30.09.2012	30.06.2012	30.09.2011	30.09.2012	30.09.2011	31.03.2012
		(un audited)	(un audited)	(un audited)	(un audited)	(Un-Audited)	(Audited)
1	Public Shareholding						
	- Number of shares (000's)	4403250	4403250	4403250	4403250	4403250	4403250
	- Percentage of Shareholding	60.79%	60.79%	60.79%	60.79%	60.79%	60.79%
2	Promoter and Promoter group Shareholding(ExcludingGDRS)						
	a) Pledged/Encumbered						
	- Number of Shares (000's)	--	--	--	--	--	--
	- Percentage of shares (As a % of total shareholding of Promoter and promoter group	--	--	--	--	--	--
	- Percentage of shares (As a % of total share Capital of the Company	--	--	--	--	--	--
	b) Non-Encumbered						
	- Number of Shares (000's)	2840500	2840500	2840500	2840500	2840500	2840500
	- Percentage of shares (As a % of total shareholding of Promoter and promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (As a % of total share Capital of the Company	39.21%	39.21%	39.21%	39.21%	39.21%	39.21%
	Particulars	The Months ended 30/09/2012					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	NIL	NIL				
	Received during the quarter	NIL	NIL				
	Disposed of during the quarter	NIL	NIL				
	Remaining unresolved at the end of the quarter	NIL	NIL				

- The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 14.10.2012
- The Accounting Standard 17 relating to Segment wise reporting is not applicable as the company operates in only one segment viz, Pharmaceuticals
- There were no complaints from investors outstanding at the beginning of the Quarter ended 30th Sep 2012 and the Company has not received any complaints during the quarter ended 30th Sep 2012
- Previous period / year figures have been regrouped wherever necessary.

Station: HYDERABAD
Date: 14.10.2012

For Concord Drugs Limited

S. Nagi Reddy
Managing director

